Global NGS-based RNA-sequencing Market Size Study & Forecast, by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, Small RNA), End-User and Regio

The Global NGS-based RNA-sequencing Market, valued at approximately USD 3.43 billion in 2024, is poised to expand at a remarkable CAGR of 17.20% from 2025 to 2035, ultimately reaching USD 19.66 billion by the end of the forecast period. NGS-based RNA sequencing (RNA-seq) has transformed transcriptomic analysis, enabling researchers and clinicians to decode gene expression profiles, identify novel transcripts, and uncover regulatory mechanisms with unprecedented depth and accuracy. Leveraging massively parallel sequencing technologies, RNA-seq facilitates the comprehensive mapping of the transcriptome, which is critical for applications ranging from cancer research and precision medicine to developmental biology and infectious disease monitoring. This surge in adoption is driven by the escalating demand for high-throughput genomic technologies, the integration of RNA-seq in clinical diagnostics, and its indispensable role in drug discovery pipelines.

The rapid acceleration in RNA-seq usage is also underpinned by a combination of falling sequencing costs, automation in sample preparation, and advances in bioinformatics that enable researchers to process and interpret massive datasets with speed and precision. According to global genomics investment trends, billions of dollars are being funneled annually into sequencing initiatives, biobank projects, and translational research programs—many of which rely on RNA-seq for biomarker discovery and therapeutic target validation. The growing application of RNA-seq in single-cell transcriptomics and epigenetic studies is opening new frontiers for understanding cellular heterogeneity and disease progression at the molecular level. Nevertheless, challenges such as data storage, standardization of analysis pipelines, and the requirement for specialized expertise may temper growth, although these are being progressively mitigated through cloud-based analysis platforms and AI-powered annotation tools.

From a regional perspective, North America currently dominates the NGS-based RNA-sequencing market, driven by its strong network of genomic research institutions, well-funded life sciences ecosystem, and the rapid integration of sequencing into clinical workflows. The United States remains at the forefront, with significant investments in precision oncology, rare disease diagnostics, and large-scale population genomics projects. Europe follows closely, fueled by government-backed genomics initiatives, collaborative research consortia, and a strong pharmaceutical industry applying RNA-seq in drug development. Asia Pacific is forecast to register the fastest growth over the next decade, as countries such as China, Japan, and India expand their genomic infrastructure, launch national sequencing programs, and attract substantial venture capital for biotech startups. Meanwhile, Latin America and the Middle East & Africa are emerging as promising markets, with increasing adoption of RNA-seq technologies in academic research and public health genomics programs.

Major market players included in this report are:
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies Ltd.
• Pacific Biosciences of California, Inc.
• QIAGEN N.V.
• BGI Genomics Co., Ltd.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd.
• PerkinElmer, Inc.
• Takara Bio Inc.
• Bio-Rad Laboratories, Inc.
• GenScript Biotech Corporation
• Eurofins Scientific SE
• Macrogen, Inc.
• 10x Genomics, Inc.

Global NGS-based RNA-sequencing Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product & Services:
• Sample Preparation
• Platforms & Consumables
• Services
• Data Analysis

By Technology:
• SBS
• SMRT
• Nanopore

By Application:
• De Novo
• Epigenetics
• Small RNA

By End-User:
• Academic & Research Institutions
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other End-Users

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more